Previous 10 | Next 10 |
home / stock / bioaf / bioaf news
GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3™ platform technology for the delivery of therapeutics across the blood-brai...
GUILFORD, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC –Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB...
GUILFORD, Conn., Nov. 03, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC –Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB...
XOMA (XOMA) has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies (BIOAF), associated with the advancement of the enzymes being investigated as potential treatments for four different lysosomal storage disorders ((LSD)) under Bioasis’ strategic all...
EMERYVILLE, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies Inc. (TSXV:BTI.V; OTCQB:BIOAF), associated with the advancement of the enzymes being investig...
GUILFORD, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform techn...
GUILFORD, Conn., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform tec...
GUILFORD, Conn., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3™ platform technology for th...
BIOASIS TECHNOLOGIES INC . (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central ner...
BIOASIS TECHNOLOGIES INC . (“ Bioasis ”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“ BBB ”) and the t...
News, Short Squeeze, Breakout and More Instantly...
Bioasis Technologies Inc Company Name:
BIOAF Stock Symbol:
OTCMKTS Market:
Bioasis Technologies Inc Website:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...